Article Information
History
- March 28, 2021.
Article Versions
- Version 1 (March 24, 2021 - 09:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Lewis Au1,2,
- Emine Hatipoglu2,3,4,
- Marc Robert de Massy3,4,
- Kevin Litchfield5,
- Andrew Rowan5,
- Rachael Thompson6,
- Desiree Schnidrig1,
- Fiona Byrne1,
- Gordon Beattie3,4,
- Stuart Horswell7,
- Nicos Fotiadis8,
- Steve Hazell9,
- David Nicol10,
- Scott Thomas Colville Shepherd1,2,
- Annika Fendler1,
- Robert Mason2,
- Jan Attig6,
- Kroopa Joshi3,4,
- Imran Uddin3,4,
- Pablo Becker3,
- Mariana Werner Sunderland3,
- Ayse Akarca11,
- Ignazio Puccio11,
- William Yang11,
- Tom Lund11,
- Kim Dhillon11,
- Marcos Duran Vasquez3,4,
- Ehsan Ghorani3,4,
- Hang Xu5,
- José Ignacio López12,
- Anna Green13,
- Ula Mahadeva13,
- Elaine Borg11,
- Miriam Mitchison11,
- David Moore4,11,
- Ian Proctor11,
- Mary Falzon11,
- Andrew Furness2,
- Lisa Pickering2,
- James L. Reading3,4,
- Roberto Salgado14,15,
- Teresa Marafioti11,
- Mariam Jamal-Hanjani4,16,17,
- on behalf of the PEACE Consortium,
- George Kassiotis6,
- Benny Chain18,19,21,
- James Larkin2,21,
- Charles Swanton4,5,18,21,
- Sergio A Quezada3,4,21,†,
- Samra Turajlic1,2,21,*,† and
- on behalf of the TRACERx Renal Consortium
- 1Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK
- 2Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
- 3Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK
- 4Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK
- 5Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK
- 6Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK
- 7Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK
- 8Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London SW3 6JJ, UK
- 9Department of Pathology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
- 10Department of Urology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
- 11Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK
- 12Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Institute, 48903 Barakaldo, Bizkaia, Spain
- 13Department of Cellular Pathology, Guy’s & St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London SE1 7EH, UK
- 14Division of Research, Peter MacCallum Cancer Centre, Melbourne VIC300, Australia
- 15Department of Pathology, GZA-ZNA Hospitals, Wilrijk, Antwerp, Belgium
- 16Cancer Metastasis Laboratory, University College London Cancer Institute, London WC1E 6DD, UK
- 17Department of Medical Oncology, University College London Hospitals, London NW1 2BU, UK
- 18Division of Infection and Immunity, University College London, London WC1E 6BT, UK
- 19University College London Cancer Institute, London WC1E 6DD, UK
- ↵†Corresponding authors - samra.turajlic{at}crick.ac.uk, s.quezada{at}ucl.ac.uk
20 Equal contributions
↵21 Equal Contributions
Posted March 28, 2021.
Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma
